Trevi Therapeutics, Inc. Overview
Pro stress-test →Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company's lead candidate, Haduvio (oral nalbuphine ER), represents a novel mechanism targeting neurologically-mediated conditions with significant unmet medical needs.
Strategic Profile
Pro stress-test →The company plans to request an End-of-Phase 2 meeting with the FDA in Q4 2025 and to initiate a Phase 3 IPF chronic cough program in H1 2026. Trevi ended Q3 2025 with $194.9 million in cash and expects a cash runway into 2028. With multiple clinical programs advancing and strong cash position, Trevi is positioned to move toward commercialization in its lead indication.
Competitive Landscape
Pro stress-test →Trevi competes in the respiratory/pruritic therapeutics space against companies including Evoke Pharma, Tioga Pharmaceuticals, Syndax Pharmaceuticals, and larger pharma players. The nalbuphine ER mechanism provides potential differentiation as a non-addictive opioid receptor modulator targeting neurologically-mediated symptoms in IPF and other conditions with limited therapeutic options.
Industry Context
Trevi Therapeutics, Inc. operates in Clinical-stage Biopharmaceuticals / Specialty Respiratory Therapeutics.
Key facts
Founded: 2011 · Headquarters: New Haven, Connecticut · Employees: unknown · Revenue: null · Market cap: $1.34B